From Bench to Bedside and Beyond
Dr. Mazyar Shadman is a blood cancer specialist at Fred Hutch Cancer Center who focuses on lymphoid malignancies. In a conversation with Bonnie Rochman, they explore the advancements in CAR T-cell therapy, particularly for large B-cell lymphoma, highlighting its impact on patient outcomes and survival rates. Takeaways * CAR T therapy is a significant advancement in cancer treatment. * The future of cancer treatment may heavily rely on CAR T advancements. * CAR T therapy represents a shift in cancer care paradigms. * It is particularly effective for large B-cell lymphoma. * Patients with relapsed disease historically had limited survival chances. * CAR T therapy has improved outcomes for high-risk patients. * 30 to 40% of patients are now being cured with CAR T therapy. * The treatment offers better quality of life compared to standard care. * Ongoing research is crucial for further advancements in CAR T. * Patient selection is key for the success of CAR T therapy.
13 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de From Bench to Bedside and Beyond!